See more : Holly Futures Co., Ltd. (3678.HK) Income Statement Analysis – Financial Results
Complete financial analysis of KORU Medical Systems, Inc. (KRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of KORU Medical Systems, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- SiS Mobile Holdings Limited (1362.HK) Income Statement Analysis – Financial Results
- Tong Hua Holding Public Company Limited (TH.BK) Income Statement Analysis – Financial Results
- MVP Holdings Inc. (MVPT) Income Statement Analysis – Financial Results
- Innovative International Acquisition Corp. (IOAC) Income Statement Analysis – Financial Results
- Credit Suisse Group AG (CS) Income Statement Analysis – Financial Results
KORU Medical Systems, Inc. (KRMD)
About KORU Medical Systems, Inc.
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.52M | 27.90M | 23.49M | 24.18M | 23.16M | 17.35M | 15.98M | 12.29M | 12.25M | 11.24M | 8.70M | 7.76M | 6.39M | 4.92M | 3.77M | 3.44M | 2.35M | 1.73M | 1.75M | 1.56M | 1.53M | 1.66M | 1.76M | 2.09M | 2.07M |
| Cost of Revenue | 11.81M | 12.53M | 9.72M | 9.24M | 8.31M | 6.54M | 6.52M | 4.72M | 4.64M | 4.56M | 3.39M | 2.82M | 2.25M | 1.66M | 1.26M | 1.24M | 899.98K | 663.51K | 728.52K | 726.46K | 723.56K | 959.54K | 1.33M | 1.11M | 1.13M |
| Gross Profit | 16.71M | 15.37M | 13.77M | 14.94M | 14.85M | 10.81M | 9.46M | 7.57M | 7.60M | 6.69M | 5.31M | 4.94M | 4.14M | 3.26M | 2.51M | 2.20M | 1.45M | 1.07M | 1.02M | 833.76K | 804.83K | 697.02K | 427.94K | 978.94K | 939.85K |
| Gross Profit Ratio | 58.59% | 55.09% | 58.62% | 61.78% | 64.13% | 62.29% | 59.20% | 61.57% | 62.08% | 59.47% | 61.04% | 63.69% | 64.77% | 66.32% | 66.53% | 63.85% | 61.67% | 61.75% | 58.27% | 53.44% | 52.66% | 42.08% | 24.33% | 46.93% | 45.50% |
| Research & Development | 5.74M | 4.96M | 2.47M | 1.30M | 740.48K | 241.12K | 60.70K | 237.49K | 207.28K | 468.15K | 218.15K | 147.58K | 90.33K | 35.52K | 27.92K | 22.44K | 59.93K | 42.03K | 41.82K | 44.03K | 42.19K | 40.27K | 40.84K | 35.34K | 80.94K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.37M | 20.61M | 17.86M | 12.03M | 9.77M | 8.20M | 7.91M | 7.77M | 5.94M | 4.79M | 3.85M | 3.54M | 2.66M | 1.97M | 1.70M | 1.31M | 1.13M | 993.42K | 984.63K | 1.07M | 876.39K | 827.87K | 635.53K | 827.99K | 1.01M |
| Other Expenses | 870.39K | 0.00 | 679.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -9.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 26.98M | 26.15M | 20.80M | 13.74M | 10.85M | 8.75M | 7.97M | 8.31M | 6.42M | 5.54M | 4.30M | 3.88M | 2.85M | 2.07M | 1.79M | 1.42M | 1.25M | 1.09M | 1.11M | 1.19M | 1.05M | 949.57K | 802.20K | 1.08M | 1.18M |
| Cost & Expenses | 38.79M | 38.68M | 30.52M | 22.98M | 19.16M | 15.29M | 14.49M | 13.03M | 11.07M | 10.10M | 7.69M | 6.70M | 5.10M | 3.73M | 3.05M | 2.66M | 2.15M | 1.76M | 1.83M | 1.92M | 1.77M | 1.91M | 2.13M | 2.19M | 2.30M |
| Interest Income | 561.33K | 145.59K | 13.08K | 42.40K | 80.66K | 28.10K | 0.00 | 2.94K | 0.00 | 5.62K | 7.43K | 8.08K | 12.85K | 8.72K | 1.35K | 8.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.89K | 3.41K | 512.00 | 4.55K | 28.28K | 31.54K | 36.39K | 47.50K | 51.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 870.39K | 587.14K | 463.13K | 418.60K | 340.23K | 309.26K | 308.71K | 300.61K | 271.57K | 283.88K | 232.96K | 190.97K | 103.98K | 65.77K | 64.80K | 79.36K | 68.20K | 60.43K | 79.09K | 81.82K | 80.55K | 81.44K | 84.84K | 84.97K | 87.80K |
| EBITDA | -9.40M | -10.19M | -6.57M | 1.61M | 4.34M | 2.37M | 1.88M | -474.20K | 1.42M | 1.36M | 1.24M | 1.25M | 1.42M | 1.30M | 774.76K | 855.89K | 261.71K | 38.29K | -9.16K | -277.54K | -165.09K | -171.12K | -289.42K | -17.38K | -149.54K |
| EBITDA Ratio | -32.96% | -36.40% | -27.84% | 16.71% | 33.36% | 18.94% | 11.22% | -3.52% | 11.79% | 12.78% | 14.35% | 16.25% | 22.00% | 26.37% | 20.87% | 24.96% | 11.15% | 12.28% | 4.55% | -17.79% | -7.44% | -10.33% | -14.12% | 5.54% | -26.45% |
| Operating Income | -10.27M | -10.78M | -7.03M | -1.25M | 585.68K | 1.16M | 1.48M | -736.25K | 1.18M | 1.15M | 1.01M | 1.06M | 1.29M | 1.19M | 721.52K | 779.01K | 193.51K | -22.14K | -88.25K | -359.35K | -245.64K | -252.56K | -374.26K | -102.35K | -237.34K |
| Operating Income Ratio | -36.01% | -38.65% | -29.93% | -5.19% | 2.53% | 6.71% | 9.29% | -5.99% | 9.65% | 10.20% | 11.58% | 13.68% | 20.17% | 24.28% | 19.11% | 22.65% | 8.24% | -1.28% | -5.06% | -23.03% | -16.07% | -15.25% | -21.28% | -4.91% | -11.49% |
| Total Other Income/Expenses | 496.40K | 105.71K | 665.09K | 60.52K | 110.74K | 12.41K | 85.18K | -40.45K | -38.81K | -72.86K | 2.78K | -24.29K | -7.97K | -1.71K | -59.06K | -54.16K | -193.51K | -232.59K | -129.56K | -40.14K | -31.53K | -14.84K | -11.24K | -2.11K | 237.34K |
| Income Before Tax | -9.77M | -10.68M | -6.36M | -1.19M | 696.42K | 1.18M | 1.57M | -776.70K | 1.14M | 1.07M | 1.01M | 1.04M | 1.28M | 1.19M | 662.46K | 724.86K | 0.00 | -254.72K | -217.82K | -399.49K | -277.17K | -267.39K | -385.50K | -104.46K | 159.46K |
| Income Before Tax Ratio | -34.27% | -38.27% | -27.09% | -4.94% | 3.01% | 6.78% | 9.82% | -6.32% | 9.33% | 9.56% | 11.62% | 13.37% | 20.05% | 24.25% | 17.55% | 21.08% | 0.00% | -14.68% | -12.48% | -25.60% | -18.13% | -16.14% | -21.92% | -5.01% | 7.72% |
| Income Tax Expense | 3.97M | -2.01M | -1.80M | 17.80K | 132.07K | 266.38K | 483.08K | -241.70K | 359.71K | 321.42K | 307.02K | 312.35K | 465.29K | 489.03K | -226.98K | -306.00K | 196.01K | 232.59K | 129.56K | 1.40K | 831.00 | 800.00 | 572.00 | 2.11K | -487.64K |
| Net Income | -13.74M | -8.66M | -4.56M | -1.21M | 564.35K | 910.57K | 1.09M | -535.00K | 782.86K | 753.12K | 703.43K | 725.76K | 815.89K | 704.09K | 889.44K | 1.03M | -2.50K | -254.72K | -217.82K | -400.89K | -278.00K | -268.19K | -386.08K | -104.46K | 250.30K |
| Net Income Ratio | -48.18% | -31.05% | -19.42% | -5.01% | 2.44% | 5.25% | 6.80% | -4.35% | 6.39% | 6.70% | 8.09% | 9.35% | 12.77% | 14.31% | 23.56% | 29.97% | -0.11% | -14.68% | -12.48% | -25.69% | -18.19% | -16.19% | -21.95% | -5.01% | 12.12% |
| EPS | -0.30 | -0.19 | -0.10 | -0.03 | 0.01 | 0.02 | 0.03 | -0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 | 0.00 | 0.01 |
| EPS Diluted | -0.30 | -0.19 | -0.10 | -0.03 | 0.01 | 0.02 | 0.03 | -0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 | 0.00 | 0.01 |
| Weighted Avg Shares Out | 45.60M | 45.00M | 44.39M | 41.93M | 38.78M | 38.13M | 37.87M | 37.83M | 37.99M | 37.63M | 36.66M | 36.01M | 34.25M | 36.24M | 35.38M | 34.83M | 32.68M | 29.87M | 26.47M | 22.70M | 23.54M | 23.50M | 23.50M | 23.35M | 20.63M |
| Weighted Avg Shares Out (Dil) | 45.60M | 45.00M | 44.39M | 41.93M | 39.06M | 38.92M | 38.39M | 37.88M | 37.99M | 37.63M | 36.66M | 36.04M | 35.10M | 36.85M | 35.38M | 34.83M | 32.68M | 29.87M | 26.47M | 22.70M | 23.54M | 23.50M | 23.50M | 23.35M | 23.12M |
KORU Medical Systems Joins Subcutaneous Drug Development & Delivery Consortium
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced its membership in the Subcutaneous (SC) Drug Development & Delivery Consortium (the...
KORU Medical Systems, Inc. (KRMD) CEO Linda Tharby on Q2 2022 Results - Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Gregory Chodaczek - Gilmartin Group Linda Tharby - President, CEO & Director Tom Adams - Interim CFO and VP, Financial Planning...
KORU Medical Systems to Participate in Canaccord Genuity's 42nd Annual Growth Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the company will participate in Canaccord Genuity's 42nd Annual...
KORU Medical Systems Announces 2022 Second Quarter Financial Results
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today...
Repro Med Systems, Inc. (KRMD) CEO Linda Tharby on Q1 2022 Results - Earnings Call Transcript
Repro Med Systems, Inc. (NASDAQ:KRMD ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Greg Chodaczek - Managing Director Linda Tharby - President & CEO Karen Fisher - CFO, Treasurer & Corporate Secretary Conference Call...
Repro Med Systems, Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 16.67% and 4.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
KORU Medical Systems Announces 2022 First Quarter Financial Results
CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of...
KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of EMPAVELI® (pegcetacoplan), Expands European Label for FreedomEdge®
CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of...
KORU Medical Systems Appoints Brian Case As Chief Technology Officer
CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced the appointment of Brian Case,...
Repro Med Systems, Inc. (KRMD) CEO Linda Tharby on Q4 2021 Results - Earnings Call Transcript
Repro Med Systems, Inc. (KRMD) CEO Linda Tharby on Q4 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports